Oxford, UK – 12 October 2023. OGT, a Sysmex Group Company and leading global provider of genomic research and diagnostic solutions, is delighted to announce its new partnership with Intelliseq, a genome informatics company and innovative provider of Next-Generation Sequencing (NGS) analysis solutions. This collaboration combines OGT's expansive SureSeq™ NGS portfolio with Intelliseq's state-of-the-art iFlow™ engine, resulting in a thorough and comprehensive NGS workflow—from sample to report. This advancement will greatly enhance lab productivity by automating the interpretation of NGS data and deliver actionable insights into cancer.
“We are excited about this partnership with Intelliseq. With the biological and clinical interpretation provided by Intelliseq, SureSeq users will have access to a comprehensive NGS solution that provides more meaningful clinical insight,” said Adrian Smith, CEO of OGT. “This partnership ensures that SureSeq users can examine any genomic content they want, while receiving the most up-to-date insight from a wide variety of clinical and biological databases.”
Similarly, CEO of Intelliseq, Klaudia Smolana, shared excitement, adding, “Our mission at Intelliseq is to simplify genome data analysis and interpretation and make it more insightful, automated and scalable. Partnering with OGT is an exciting opportunity for Intelliseq to expand the reach of our advanced NGS reporting solutions. Our technology combined with OGT’s expertise in NGS solutions will enable laboratories to unlock the full potential of their genomic data and offer a complete analysis. We look forward to the positive impact this collaboration will have on the genomics community.”
This partnership between OGT and Intelliseq exemplifies a shared commitment to innovation and customer-centric solutions. Both companies believe that by combining their strengths, they can provide laboratories worldwide with the tools they need to deliver accurate, personalized and actionable insights.
To learn more about combining the SureSeq NGS workflow from OGT with Intelliseq's intuitive iFlow™ engine for complete genomic NGS analysis and reporting, please contact John Vincent, PhD, Director, Business and Market Development, North America at OGT at John.Vincent@ogt.com or David Hanna, Chief Commercial Officer (CCO) at Intelliseq at david@intelliseq.pl.
OGT, a Sysmex Group company, is a leading global provider of clinical and diagnostic genomic solutions that are created for scientists by scientists - including CytoCell®, CytoSure® and SureSeq™ ranges of FISH, microarray and NGS products. The company is dedicated to creating products that enable researchers and clinical decision makers to reach the right care decisions for each patient, every time. OGT strives to unlock the future of genetic clinical care with a commitment to working in partnership with its customers - not only by sharing its expertise of 25 years at the forefront of genetic endeavour, but also by working closely with scientists to understand their unique challenges, and to customise its approach to meet their exact needs. Dedicated to improving clinical care, OGT believes that through partnership—together—we’ll achieve more.
CytoSure®, SureSeq™ and myProbes®: For Research Use Only, not for use in diagnostic procedures. CytoCell®: Some products may not be available in your region.
Sysmex, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." To realize this vision, Sysmex identifies and verifies prioritized Sustainable Development Goals (SDGs) and materiality (priority issues), thereby maintaining its growth as a company that generates both social and economic value. Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives. The company employs more than 10,000 employees worldwide. Sysmex Corporation is listed in the Prime Market on the Tokyo Stock Exchange.
For more information about Sysmex Corporation and its affiliate companies, please visit www.sysmex.co.jp/en/.
Intelliseq is a genome informatics company, focused on the development of novel algorithms and bioinformatics tools devoted to the interpretation of the human DNA sequence. Backed by a team of skilled scientists and bioinformatics experts, their state-of-the-art iFlow™ engine offers tailored solutions for researchers, clinicians, and biotech companies, enabling them to unlock the vast potential of genomic data in personalized medicine and disease research. The system drives lab efficiency through streamlined raw DNA data-to-reporting workflows in a variety of genome medicine applications.
For more information on Intelliseq, please visit https://intelliseq.com/
Enhanced NGS portfolio includes Interpret Software updates and enables rapid and confident variant detection even in difficult-to-sequence regions.
Read
Launch of two NGS panels enables comprehensive detection of genetic abnormalities involved in breast and ovarian cancer, and myeloid disorders.
Read
New content and Interpret NGS analysis software detection capabilities include BCR-ABL and KMT2A-PTD detection.
Read
Visit USA site
Visit Canada site
